Hims & Hers, which called the lawsuit a "blatant attack by a Danish company on millions of Americans who rely on compounded medications for access to personalized care," said it plans to "continue to fight to provide choice, affordability, and access." Why This News is Important Hims & Hers pulling its copycat pill from the market could reduce competition for Novo Nordisk
This activity is supported by GSK and Pfizer
However, there is only one approved drug, setmelanotide for POMC-LEPR deficiency [10], and there is no treatment for other POMC-MC4R pathway-deficient diseases, such as POMC-null, MSH-deficiency, and patients with PWS with obesity
Decathlon aconseja consultar a un mdico o dietista cuando el consumo supere los dos meses
[10] Day JW, et al
To get it in your inbox, subscribe here